7-methyl-1-(piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one | 739357-15-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 7-methyl-1-(piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one
• 英文别名: 4-methyl-3-piperidin-4-yl-1H-benzimidazol-2-one
• CAS: 739357-15-4
• 化学式: C₁₃H₁₇N₃O
• 分子量: 231.297
• InChiKey: AFQMHOLABZKCFE-UHFFFAOYSA-N

物化性质

• 密度：
  1.188±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  44.4
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  7-methyl-1-(piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one 、 6-喹啉乙酸 在 1-羟基苯并三唑 作用下， 生成 7-methyl-1-(1-(2-(quinolin-6-yl)acetyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one
  参考文献：
  名称：

  HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME

  摘要：

  由式XI表示的杂环化合物，其药用盐、溶剂合物，或其药用盐的溶剂合物，以及其用途和含有该化合物的组合物。该化合物在结构上是新颖的，并具有良好的STAT5抑制活性。

  公开号：

  EP3960736A1
• 作为产物：
  描述：

  1-Ethoxycarbonyl-4-[(2-methyl-6-nitrophenyl)amino]piperidine 在 platinum on activated charcoal sodium hydroxide 、 甲酸铵 、 三乙胺 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 4.0h， 生成 7-methyl-1-(piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one
  参考文献：
  名称：

  Discovery and SAR studies of a novel series of noncovalent cathepsin S inhibitors

  摘要：

  A novel series of competitive, reversible cathepsin S (Cats) inhibitors was discovered and optimized. The 4-(2-keto-1-benzimidazolinyl)-piperidin-1-yl moiety was found to be an effective replacement for the 4-arylpiperazin-1-yl group found in our earlier series of Cats inhibitors. This replacement imparted improved PK properties as well as decreased off-target activity. Optimization of the ketobenzimidazole moiety led to the discovery of the lead compound JNJ 10329670, which represents a novel class of selective, noncovalent, reversible, and orally bioavailable inhibitors of cathepsin S. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.01.045

文献信息

• [EN] DIMERIC COMPOUNDS OF PIPERIDINE, PIPERAZINE OR MORPHOLINE OR THEIR 7-MEMBERED ANALOGS SUITABALE FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS<br/>[FR] COMPOSES DIMERES DE PIPERIDINE, PIPERAZINE OU MORPHOLINE OU LEURS PRODUITS ANALOGUES A 7 ELEMENTS, DESTINES AU TRAITEMENT DE MALADIES NEURODEGENERATIVES
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2006008259A1

  公开（公告）日：2006-01-26

  Formula (I’’), the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof.

  公式(I'')，N-氧化物形式，药用可接受的增加盐和它们的立体化学异构形式。
• [EN] NOVEL PIPERIDINE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS DE PIPÉRIDINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2016087352A1

  公开（公告）日：2016-06-09

  The invention relates to a compound of formula (I) wherein A1, A2 and R1to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

  这项发明涉及一种化合物，其化学式为（I），其中A1，A2和R1至R3的定义如描述和索赔中所述。化合物的化学式（I）可用作药物。
• Phenoxyalkylamine derivatives useful as opioid receptor agonists
  申请人：——

  公开号：US20030171370A1

  公开（公告）日：2003-09-11

  A medicament useful for preventive and/or therapeutic treatment of nerve system diseases which comprises, as an active ingredient, a compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof: 1 wherein, X represents a group represented by the following general formula (II), (III), (IV), (V), or (VI), 2 “A” represents a saturated or unsaturated 3- to 6-membered carbocyclic group and the like, “B” represents CH 2 and the like, “n” represents 0 to 2, R 1 represents a hydrogen atom, a halogen atom and the like, R 2 , R 3 , and R 7 to R 14 represent a hydrogen atom, a lower alkyl group which may be substituted and the like, R 4 represents a hydrogen atom, a lower alkyl group which may be substituted and the like, R 5 represents a hydrogen atom, a halogen atom and the like, R 6 represents a saturated or unsaturated monocyclic or bicyclic carbocyclic group and the like, and R 5 and R 6 , R 7 and R 8 , R 9 and R 10 , or R 11 and R 12 may bind to each other to form a cyclic structure.

  一种用于预防和/或治疗神经系统疾病的药物，其活性成分为以下通用式（I）或其药理学可接受的盐所代表的化合物： 其中，X代表以下通用式（II）、（III）、（IV）、（V）或（VI）所代表的基团，“A”代表饱和或不饱和的3-至6-成员碳环基团等，“B”代表CH2等，“n”代表0至2，R1代表氢原子、卤素原子等，R2、R3和R7至R14代表氢原子、可能被取代的较低烷基基团等，R4代表氢原子、可能被取代的较低烷基基团等，R5代表氢原子、卤素原子等，R6代表饱和或不饱和的单环或双环碳环基团等，且R5和R6、R7和R8、R9和R10，或R11和R12可以结合在一起形成环状结构。
• Phenoxyalkylamine derivatives useful as opioid delta receptor ligands
  申请人：Tsushima Masaki

  公开号：US20050148583A1

  公开（公告）日：2005-07-07

  A medicament useful for preventive and/or therapeutic treatment of nerve system diseases which comprises, as an active ingredient, a compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof: wherein, X represents a group represented by the following general formula (II), (III), (IV), (V), or (VI), “A” represents a saturated or unsaturated 3- to 6-membered carbocyclic group and the like, “B” represents CH 2 and the like, “n” represents 0 to 2, R 1 represents a hydrogen atom, a halogen atom and the like, R 2 , R 3 , and R 7 to R 14 represent a hydrogen atom, a lower alkyl group which may be substituted and the like, R 4 represents a hydrogen atom, a lower alkyl group which may be substituted and the like, R 5 represents a hydrogen atom, a halogen atom and the like, R 6 represents a saturated or unsaturated monocyclic or bicyclic carbocyclic group and the like, and R 5 and R 6 , R 7 and R 8 , R 9 and R 10 , or R 11 and R 12 may bind to each other to form a cyclic structure.

  一种用于神经系统疾病的预防和/或治疗的药物，其包括以下通式（I）所表示的化合物或其药学上可接受的盐作为活性成分： 其中，X代表以下通式（II），（III），（IV），（V）或（VI）所表示的基团，“A”代表饱和或不饱和的3-至6-成员的碳环基团等，“B”代表CH2等，“n”代表0至2，“R1”代表氢原子，卤原子等，“R2”，“R3”和“R7”至“R14”代表氢原子，可被取代的较低烷基基团等，“R4”代表氢原子，可被取代的较低烷基基团等，“R5”代表氢原子，卤原子等，“R6”代表饱和或不饱和的单环或双环碳环基团等，“R5”和“R6”，“R7”和“R8”，“R9”和“R10”，或“R11”和“R12”可以结合在一起形成环状结构。
• Benzimidazolone derivatives
  申请人：——

  公开号：US20040147506A1

  公开（公告）日：2004-07-29

  This invention relates to benzimidazolone derivatives, represented by compounds of a general formula [I] 1 [in which R 1 and R 2 stand for, e.g., hydrogen atoms; R 3a , R 3b , R 4 , R 5 stand for, e.g., hydrogen atoms and alkyl groups; R 6 stands for e.g., aryl or heteroaryl groups; A ring stands for 5- to 8-membered aliphatic heterocyclic ring containing one nitrogen atom; and Z stands for carbonyl group or sulfonyl group]. The benzimidazolone derivatives of the invention exhibit antagonism to muscarinic acetylcholine receptors, and are useful as treating agent and/or prophylactic of Parkinson's disease, drug-induced parkinsonism, dystonia, akinesia, pancreatitis, bilestone/cholecystitis, biliary dyskinesia, achalasia, pain, itch, cholinergic urticaria, irritable bowel syndrome, vomiting, nausea, dizziness, Meniere's disease, motion sickness and urinary disturbance.

  本发明涉及苯并咪唑酮衍生物，其由一般式[I]中的化合物表示，其中R1和R2代表氢原子；R3a、R3b、R4、R5代表氢原子和烷基基团；R6代表芳基或杂环芳基基团；A环代表含有一个氮原子的5-至8-成员脂肪族杂环环；Z代表羰基团或磺酰基团。本发明的苯并咪唑酮衍生物表现出对肌动蛋白乙酰胆碱受体的拮抗作用，可用作帕金森病、药物诱导的帕金森综合征、肌张力障碍、运动障碍、胰腺炎、胆石/胆囊炎、胆道运动障碍、食管失弛缓症、疼痛、瘙痒、胆碱能荨麻疹、肠易激综合征、呕吐、恶心、眩晕、梅尼埃病、晕动病和尿液障碍的治疗剂和/或预防剂。